Robert von Rosen
Attorney at Law
Partner

Robert von Rosen Robert von Rosen Robert von Rosen Robert von Rosen


Robert von Rosen is a partner in the Basel office of Walder Wyss. His practice focuses on domestic and international M&A transactions. He also advises corporate clients on all matters of corporate and commercial law related to their daily operations. A further focus of Robert von Rosen is banking, finance and capital markets law.

After completing a two-year internship at Frankfurter Sparkasse, Frankfurt, Germany (diploma in banking [Bankkaufmann] 1998), Robert von Rosen was educated at the Albert-Ludwigs-University Freiburg, Germany (law exam 2004, bar exam 2006). From 2001 to 2003, he worked as scientific assistant at the professorship in civil law, industrial property protection and copyright law, Albert-Ludwigs-University Freiburg, Germany. Further, he completed several internships, inter alia, in New York, Frankfurt and Zurich until 2006. Prior to joining Walder Wyss, Robert von Rosen worked during eight years (2006-2014) for a leading Swiss law firm with offices in Basel, Zurich and Bern (2010-2014 as a senior associate), supplemented by a secondment at the Swiss Financial Market Supervisory Authority FINMA in 2011.

Robert von Rosen‘s professional languages are German and English. He is registered with the Basel bar registry.

Contact
Robert von Rosen
Direct phone: + 41 58 658 14 63


Walder Wyss Ltd.
Aeschenvorstadt 48
P.O. Box 633
4010 Basel
Switzerland
Phone +41 58 658 10 00
Fax +41 58 658 59 59
vCard


Practice Areas

Robert von Rosen Robert von Rosen Robert von Rosen Robert von Rosen

Robert von Rosen
Attorney at Law
Partner

Robert von Rosen is a partner in the Basel office of Walder Wyss. His practice focuses on domestic and international M&A transactions. He also advises corporate clients on all matters of corporate and commercial law related to their daily operations. A further focus of Robert von Rosen is banking, finance and capital markets law.

After completing a two-year internship at Frankfurter Sparkasse, Frankfurt, Germany (diploma in banking [Bankkaufmann] 1998), Robert von Rosen was educated at the Albert-Ludwigs-University Freiburg, Germany (law exam 2004, bar exam 2006). From 2001 to 2003, he worked as scientific assistant at the professorship in civil law, industrial property protection and copyright law, Albert-Ludwigs-University Freiburg, Germany. Further, he completed several internships, inter alia, in New York, Frankfurt and Zurich until 2006. Prior to joining Walder Wyss, Robert von Rosen worked during eight years (2006-2014) for a leading Swiss law firm with offices in Basel, Zurich and Bern (2010-2014 as a senior associate), supplemented by a secondment at the Swiss Financial Market Supervisory Authority FINMA in 2011.

Robert von Rosen‘s professional languages are German and English. He is registered with the Basel bar registry.

Robert von Rosen
Direct phone: + 41 58 658 14 63

Walder Wyss Ltd.
Aeschenvorstadt 48
P.O. Box 633
4010 Basel
Switzerland
Phone +41 58 658 10 00
Fax +41 58 658 59 59


vCard

Practice Areas

No publication found with your search criteria.


Deals and Cases

BC Platforms CHF 10 Mio. B Round

Walder Wyss advises BC Platforms AG, Basel, on its Series B financing Round. The financing round amounts to CHF 10 mio. was subscribed by Debiopharm Innovation Fund and Finnish Industry Investment as lead investors as well as by existing shareholders.

The Walder Wyss teams consisted of Alexander Gutmans (Partner, Corporate Venture Capital, Life Sciences), Robert von Rosen (Partner, Corporate) and Vanessa C. Haubensak (Associate, Corporate).


RWS acquires LUZ, Inc.

RWS Holdings plc, a world leading provider of intellectual property support services (patent translations, international patent filing solutions and searches), commercial translations and linguistic validation, has completed the acquisition of 100% of LUZ, Inc., a market leading Life Sciences language services provider based in San Francisco, for a cash consideration of USD82.5m.

Based in San Francisco, LUZ is a market leading life sciences translation provider, specializing in medical devices and regulatory activities. LUZ services a number of the world’s leading pharmaceutical and medical device manufacturers, enjoying a preferred supplier relationship with certain customers. The acquisition strengthens RWS’s leading position in global Life Sciences both in the US and Europe.

Walder Wyss acted as RWS' legal advisor on that transaction. The team was led by Robert von Rosen (Partner, Corporate M&A) and further included Alexander Gutmans (Partner, Corporate M&A), Michael Isler (Partner, IP/IT), David M. Hill (Associate, Employment) and Jonas Knechtli (Associate, Corporate/Commercial).


Spadina House AG acquires SkyVision

Spadina House AG acquires all shares in SkyVision Global Networks Ltd., a global IP telecommunication service provider which offers solutions over satellite and fibre optic systems. The acquisition supplements Spadina's portfolio in satellite communication providers. The transaction was highly complex and involved multiple global jurisdictions and telecommunication licensing regimes.

Walder Wyss advised Spadina House AG regarding all Swiss law aspects of this transaction. The team was led by Robert von Rosen (Managing Associate, Corporate/M&A) and further included Samuel Duerr (Partner, Tax).


Acino divests its patch business to Luye Pharma Group Ltd.

Luye Pharma Group Ltd. has entered into an agreement to acquire the TDS business from Acino, through the purchase of the entire issued share capital of Acino AG and Acino Supply AG for EUR 245,000,000. The target group is a Europe based global leader in advanced transdermal drug delivery systems (TDS) and is one of the largest independent TDS manufacturers in Europe. Closing is expected to occur in the second half of 2016.

Walder Wyss comprehensively advised Luye Pharma regarding the Swiss law aspects of this transaction. The team was led by Alexander Gutmans (Partner, Corporate/M&A) and Robert von Rosen (Managing Associate, Corporate) and also included Dirk Spacek (Associate, IP/IT) and Jessica Aeschbach Flórez (Associate, Corporate).


Bayer and CRISPR Therapeutics form Gene Editing Joint Venture

Bayer and the Basel domiciled CRISPR Therapeutics AG have entered into an agreement to create a joint venture (JV) to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. Bayer will provide a minimum of USD 300 million in R&D investments to the JV over the next five years. In addition, Bayer will acquire a minority stake in CRISPR Therapeutics for USD 35 million in cash.

Walder Wyss acted as legal advisor to Bayer regarding Swiss law aspects. The team included Alexander Gutmans (Partner, Corporate/M&A), Alex Nikitine (Partner, Corporate/M&A)  and Robert von Rosen (Managing Associate, Corporate/M&A).


Curriculum Vitae PDF